GlassScriptPhysician profile
Morgan Ashley Shafer
NPI 1487120457
$3,350.79
in general payments reported to CMS, 2019-2025
44 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $781 · 2022: $335 · 2023: $895 · 2024: $901 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.49 |
| Education | $314.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $785.88 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $302.02 | 2024-2025 | Opdivo, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $227.00 | 2022-2024 | Calquence, Lynparza |
| Sanofi-Aventis U.S. LLC | $164.94 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $144.02 | 2023-2024 | Monoferric |
| Puma Biotechnology, INC. | $135.46 | 2021-2022 | |
| Eisai INC. | $132.92 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $130.37 | 2023-2024 | Keytruda, Welireg |
| Taiho Oncology, INC. | $122.69 | 2021 | |
| Myriad Genetic Laboratories, INC. | $120.79 | 2025 | Myrisk |
| Janssen Biotech, INC. | $114.23 | 2021-2025 | Erleada, Balversa, Akeega |
| Novartis Pharmaceuticals Corporation | $86.83 | 2022-2023 | |
| Genzyme Corporation | $68.17 | 2021-2024 | |
| Glaxosmithkline, LLC. | $68.01 | 2023-2025 | Ojjaara, Jemperli |
| Regeneron Healthcare Solutions, INC. | $60.45 | 2023-2024 | Libtayo |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Shafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.